SLFN11 informs on standard of care and novel treatments in a wide range of cancer models

BACKGROUND: Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinical significance of SLFN11 as a predictive biomark...

全面介紹

Na minha lista:
書目詳細資料
發表在:Br J Cancer
Main Authors: Winkler, Claudia, Armenia, Joshua, Jones, Gemma N., Tobalina, Luis, Sale, Matthew J., Petreus, Tudor, Baird, Tarrion, Serra, Violeta, Wang, Anderson T., Lau, Alan, Garnett, Mathew J., Jaaks, Patricia, Coker, Elizabeth A., Pierce, Andrew J., O’Connor, Mark J., Leo, Elisabetta
格式: Artigo
語言:Inglês
出版: Nature Publishing Group UK 2020
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7921667/
https://ncbi.nlm.nih.gov/pubmed/33339894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01199-4
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍